Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative chemotherapy versus surveillance in upper tract urothelial cancer
2011-002577-33Phase 3Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin and carboplatin in upper tract urothelial carcinoma (UTUC), Renal pelvis urothelial carcinoma (UTUC) and ureteral urothelial carcinoma (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
gemcitabinecisplatincarboplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)Renal pelvis urothelial carcinoma (UTUC)ureteral urothelial carcinoma
Beyond the preview
Go deeper on 2011-002577-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002577-33.